Yaz Lawsuit Filed by DVT & Pulmonary Embolism Victim

Yaz is a type of oral birth control that is also marketed under the names Yasmin, Beyaz and Ocella. It was approved by the Food and Drug Administration (FDA) in 2001. Despite the approval of Yaz, the medication was quickly linked to a number of side effects, including an increased risk of pulmonary embolism, deep vein thrombosis, stroke, blood clots, and even death.

In 2002, the British Medical Journal published a report that described the side effects linked to Yaz, Yasmin, Beyaz and Ocella birth control. The report outlined 40 different women who had experienced deep vein thrombosis while taking the Yasmin line of birth control pills. This initial report was followed by a second report in 2003 looking at five more situations of deep vein thrombosis in Yasmin/Yaz/Beyaz/Ocella patients, including two where the women in question died.

Despite this international evidence, the makers of Yaz, Yasmin, Ocella and Beyaz did not withdraw the drugs from the market. Instead, they continued to market Yaz, Yasmin, Ocella and Beyaz as an effective form of birth control and kept mention of the potential side effects of taking Yaz to a minimum in their advertisements. The FDA cautioned the manufacturers twice for misleading consumers with this style of advertising, but did not force the companies to change their safety labeling until 2011.

After women around the world realized the extent of the risks of cardiac injury from the birth control, many filed Yaz lawsuits, Beyaz lawsuit, Ocella lawsuits and Yasmin lawsuits. They claimed that they were misled by the information distributed by the manufacturers of Yaz about the safety of the drug, and that the absence of warnings represented a deliberate attempt by the manufacturers to hide the side effects of the drug from the public.